Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)

John W. Day; Jerry R. Mendell; Eugenio Mercuri; Richard S. Finkel; Kevin A. Strauss; Aaron Kleyn; Sitra Tauscher-Wisniewski; Francis Fonyuy Tukov; Sandra P. Reyna; Deepa H. Chand

doi:10.1007/s40264-021-01130-7

Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)

John W. Day
, Jerry R. Mendell
, Eugenio Mercuri
, Richard S. Finkel
, Kevin A. Strauss
, Aaron Kleyn
, Sitra Tauscher-Wisniewski
, Francis Fonyuy Tukov
, Sandra P. Reyna
, Deepa H. Chand

Division of Nephrology, Hypertension & Apheresis

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

Original language	English
Pages (from-to)	191-192
Number of pages	2
Journal	Drug Safety
Volume	45
Issue number	2
DOIs	https://doi.org/10.1007/s40264-021-01130-7
State	Published - Feb 2022

Access to Document

10.1007/s40264-021-01130-7

Cite this

Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2022). Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6). Drug Safety, 45(2), 191-192. https://doi.org/10.1007/s40264-021-01130-7

@article{3b42df2c07854739929ef95ab73280db,

title = "Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)",

abstract = "In the original publication of the article, footnote marker {\textquoteleft}b{\textquoteright} was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.",

author = "Day, \{John W.\} and Mendell, \{Jerry R.\} and Eugenio Mercuri and Finkel, \{Richard S.\} and Strauss, \{Kevin A.\} and Aaron Kleyn and Sitra Tauscher-Wisniewski and Tukov, \{Francis Fonyuy\} and Reyna, \{Sandra P.\} and Chand, \{Deepa H.\}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2022",

month = feb,

doi = "10.1007/s40264-021-01130-7",

language = "English",

volume = "45",

pages = "191--192",

journal = "Drug Safety",

issn = "0114-5916",

number = "2",

}

Day, JW, Mendell, JR, Mercuri, E, Finkel, RS, Strauss, KA, Kleyn, A, Tauscher-Wisniewski, S, Tukov, FF, Reyna, SP & Chand, DH 2022, 'Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)', Drug Safety, vol. 45, no. 2, pp. 191-192. https://doi.org/10.1007/s40264-021-01130-7

TY - JOUR

T1 - Correction to

T2 - Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)

AU - Day, John W.

AU - Mendell, Jerry R.

AU - Mercuri, Eugenio

AU - Finkel, Richard S.

AU - Strauss, Kevin A.

AU - Kleyn, Aaron

AU - Tauscher-Wisniewski, Sitra

AU - Tukov, Francis Fonyuy

AU - Reyna, Sandra P.

AU - Chand, Deepa H.

PY - 2022/2

Y1 - 2022/2

N2 - In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

AB - In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

UR - https://www.scopus.com/pages/publications/85121657598

U2 - 10.1007/s40264-021-01130-7

DO - 10.1007/s40264-021-01130-7

M3 - Comment/debate

C2 - 34940960

AN - SCOPUS:85121657598

SN - 0114-5916

VL - 45

SP - 191

EP - 192

JO - Drug Safety

JF - Drug Safety

IS - 2

ER -

Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this